The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk

For Immediate Release

Chicago, IL – June 26, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Novartis NVS, Roche (OTCMKTS: RHHBY – Free Report ), Shire SHPG, Neos NEOS and Novo Nordisk NVO.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free .

Here are highlights from Monday's Analyst Blog:

Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod

This week's highlights include positive data from Novartis NVS while the FDA approved a couple of attention deficit hyperactive disorder ADHD drugs.

Recap of the Week's Most Important Stories

Novartis Eye Drug Hits Endpoints; CANTOS Data Impresses: Novartis' experimental eye drug, RTH528, was found to be non-inferior to Regeneron's blockbuster drug Eylea (aflibercept) in a couple of late-stage studies. Adverse event rates were also comparable. The studies were conducted in patients with neovascular age-related macular degeneration (nAMD). Novartis expects to file for approval next year. If approved, RTH528 could have a competitive edge due to a less frequent dosing regimen.

Novartis also impressed with data from a late-stage study (CANTOS) on ACZ885 (canakinumab). Top-line data showed that ACZ885 plus standard of care therapy reduces cardiovascular risk in people with a prior heart attack and inflammatory atherosclerosis. Novartis intends to start discussions with regulatory authorities.

So far in 2017, Novartis has outperformed the Zacks categorized Large Cap Pharmaceuticals industry with shares gaining 18.5% while the industry is up 13.2%.

Subcutaneous Rituxan Formulation Approved: A subcutaneous formulation of Roche's (OTCMKTS: RHHBY – Free Report ) multi-billion dollar drug, Rituxan, gained FDA approval this week. Approval was largely expected considering an FDA advisory panel had voted unanimously in favor of approving the formulation for certain types of blood cancer. Formulated using rHuPH20, a technology licensed from Halozyme, Rituxan Hycela can be administered in five to seven minutes compared to an hour and a half or more for the intravenous formulation.

FDA Green Light for Shire ADHD Drug: Shire 's SHPG ADHD drug, Mydayis, has finally gained FDA approval. Mydayis or SHP465, as it was previously referred to, has had a long journey with the FDA initially giving an approvable letter way back in May 2007. At that time, the agency had asked for additional studies. Shire, a key player in the ADHD market, expects to launch the long-lasting once-daily treatment in the third quarter of 2017. The ADHD market is huge though highly genericized. About 10.5 million adults in the U.S. are estimated to have ADHD (Read more: Shire's ADHD Drug Mydayis Receives Approval in U.S. ).

Neos ADHD Drug Too Gets FDA Nod: Shire was not the only company to gain FDA approval for an ADHD drug this week. The FDA also gave its nod to Neos' NEOS Cotempla XR-ODT, making it the first and only methylphenidate extended-release orally disintegrating tablet to be approved for the treatment of ADHD in patients 6 to 17 years old.

With this approval, Neos has both a branded methylphenidate as well as a branded amphetamine product available in an extended-release orally disintegrating tablet dosage form. Cotempla XR-ODT will be launched this Fall.

Novo Nordisk's Victoza Label Expansion Plans Get FDA Panel Support: Novo Nordisk's NVO Victoza (liraglutide) got a favorable vote from an FDA advisory panel regarding the inclusion of data from the cardiovascular outcomes study LEADER in the drug's label. The Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) voted 19-0 in favor of the use of Victoza in type II diabetes patients not being associated with excess cardiovascular risk. The panel voted 17-2 in favor of the study providing enough evidence of reduction in cardiovascular risk in type II diabetes patient on Victoza. With cardiovascular disease being a leading cause of death in type II diabetes patients, the addition of a cardiovascular indication would boost Victoza's sales potential (Read more: Novo Nordisk's Victoza Gets FDA Panel Nod for Label Expansion ).

Novo Nordisk is a Zacks Rank #2 (Buy) stock. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here .

The NYSE ARCA Pharmaceutical Index was up almost 4% over the last five trading sessions with the sector reacting favorably to rumors that steps taken by the Trump administration to drive down drug prices will not be as draconian as previously expected. Among major stocks, Bristol-Myers was up 5.6% while Merck gained 4.5%. Over the last six months, AstraZeneca was up 30.1% while Bristol-Myers was down 2.4% (See the last pharma stock roundup here: J&J, Lilly Present Data, Merck Keytruda Study Enrolment Paused ).

The Best & Worst of Zacks

Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 "Strong Buys" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 "Strong Sells." Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on NVS - FREE

Get the full Report on RHHBY - FREE

Get the full Report on SHPG - FREE

Get the full Report on NEOS - FREE

Get the full Report on NVO - FREE

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook: https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.